Direct Portal Pressure Measurement Via Endoscopic Ultrasound in Advanced Chronic Liver Disease (EVADIPP)

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Feb 15, 2024

Keywords

ClinConnect Summary

The clinical trial titled EVADIPP is studying a new, less invasive way to measure pressure in the portal vein, which is the vein that carries blood to the liver. This procedure, called endoscopic ultrasound-guided portal pressure gradient measurement (EUS-PPG), aims to help doctors understand how well patients respond to a specific type of medication called non-selective beta-blockers (NSBBs). The trial will include a large number of patients with advanced liver disease who have recently been diagnosed with significant portal hypertension, which can lead to complications like varices (enlarged veins) in the esophagus and stomach.

To participate in this study, individuals should be between the ages of 18 and 75 and have newly diagnosed varices or signs that suggest significant portal hypertension. They should not have previously received treatment with NSBBs. Patients with severe liver disease, liver cancer, or a blocked portal vein will not be eligible. Participants can expect to undergo the EUS-PPG procedure, which is designed to be safe and provide valuable information about their condition. This trial will help improve understanding of portal hypertension and how to better treat patients facing this serious health issue.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed esophago-gastric varices or with high suspicion of CSPH at non-invasive tests (porto- systemic collaterals at imaging, platelet count \<150.000 x mm3, spleen size \>13 cm in the largest axis, alteration of elastography parameters of the liver or spleen)
• • naïve to treatment with NSBBs,
• Exclusion Criteria:
• • Child Pugh \>A6
• • Hepatocellular carcinoma
• • Portal vein thrombosis